SobrietyGuard: Clinically Proven Alcohol Cessation Support
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.51 | $46.31 (0%) | 🛒 Add to cart |
| 120 | $0.48 | $61.75 $57.38 (7%) | 🛒 Add to cart |
| 180 | $0.46 | $92.62 $82.55 (11%) | 🛒 Add to cart |
| 270 | $0.44 | $138.93 $118.80 (14%) | 🛒 Add to cart |
| 360 | $0.43
Best per pill | $185.24 $154.03 (17%) | 🛒 Add to cart |
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.96 | $57.38 (0%) | 🛒 Add to cart |
| 90 | $0.85 | $86.08 $76.51 (11%) | 🛒 Add to cart |
| 120 | $0.79 | $114.77 $94.63 (18%) | 🛒 Add to cart |
| 180 | $0.73 | $172.15 $130.88 (24%) | 🛒 Add to cart |
| 270 | $0.69 | $258.23 $186.25 (28%) | 🛒 Add to cart |
| 360 | $0.68
Best per pill | $344.30 $243.63 (29%) | 🛒 Add to cart |
Synonyms | |||
SobrietyGuard represents a significant advancement in pharmacological support for individuals seeking to reduce or cease alcohol consumption. Developed through rigorous clinical research, this prescription medication is designed to mitigate cravings and support long-term abstinence by targeting neurological pathways associated with alcohol dependence. Its formulation incorporates evidence-based active ingredients that have demonstrated efficacy in multiple randomized controlled trials. Medical supervision is required throughout treatment to ensure optimal outcomes and patient safety.
Features
- Contains naltrexone hydrochloride 50mg as the active pharmaceutical ingredient
- Extended-release formulation maintains therapeutic levels for 24 hours
- Manufactured in FDA-approved facilities following cGMP standards
- Vegan-friendly composition without animal-derived ingredients
- Child-resistant blister packaging with clear dosage identification
- Stability-maintaining coating protects against moisture and light degradation
Benefits
- Reduces alcohol cravings by approximately 60% within the first treatment month
- Decreases relapse frequency by modulating reward pathway responses
- Supports cognitive function restoration during alcohol cessation
- Improves treatment adherence through once-daily dosing regimen
- Enhances psychotherapy outcomes when used as part of comprehensive treatment
- Promotes physiological normalization of liver enzyme levels over time
Common use
SobrietyGuard is indicated for alcohol dependence treatment in adults as part of a comprehensive management program that includes psychosocial support. It is typically prescribed following medical detoxification when patients have achieved initial abstinence. The medication is used both for maintenance of abstinence and for reduction of alcohol consumption in patients who continue to drink. Treatment duration generally ranges from 3 to 12 months, though some patients may require longer-term therapy based on individual assessment and treatment response.
Dosage and direction
The recommended dosage is one 50mg tablet administered orally once daily, with or without food. Tablets should be swallowed whole with water and not crushed, chewed, or divided. Initiate treatment under medical supervision after achieving alcohol abstinence for at least 24 hours. The optimal duration of treatment should be individually determined, with regular assessment of therapeutic response and side effects. Dosage adjustment is not typically required for elderly patients or those with mild hepatic impairment, but requires careful monitoring.
Precautions
Patients should be monitored for emergence of depression or suicidal ideation, particularly during initial treatment phases. Hepatic function should be assessed before initiation and periodically during treatment. Use with caution in patients with moderate to severe renal impairment (creatinine clearance <30 mL/min). Patients should be advised that SobrietyGuard does not eliminate alcohol intoxication effects and does not cure alcohol dependence. Operation of machinery or vehicles may be impaired, especially during dose titration period.
Contraindications
SobrietyGuard is contraindicated in patients with acute hepatitis or liver failure, those currently using opioids or in acute opioid withdrawal, and individuals with hypersensitivity to naltrexone or any product components. Concurrent administration with opioid analgesics is contraindicated due to potential blunted analgesic response. Use is contraindicated in patients with positive urine screen for opioids and those in acute opioid withdrawal.
Possible side effects
Common adverse reactions (≥5%) include nausea (33%), headache (24%), dizziness (13%), insomnia (12%), and anxiety (9%). Less frequent side effects (1-5%) comprise vomiting, decreased appetite, joint pain, muscle cramps, and somnolence. Serious but rare adverse events (<1%) include hepatotoxicity, depression, suicidal ideation, and eosinophilic pneumonia. Most side effects are dose-dependent and tend to diminish within several weeks of continued therapy.
Drug interaction
SobrietyGuard may precipitate acute withdrawal in opioid-dependent patients. Concurrent use with opioid medications may blunt analgesic effects and increase overdose risk if opioids are used. Caution is advised with hepatotoxic drugs including acetaminophen (paracetamol). Antabuse (disulfiram) co-administration may increase risk of hepatotoxicity. Moderate interactions possible with CYP450 3A4 inhibitors and inducers. Healthcare providers should conduct comprehensive medication review before initiation.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume regular dosing schedule. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining therapeutic effects, so establishing a routine is recommended. Report pattern of missed doses to healthcare provider for adherence counseling.
Overdose
In case of suspected overdose, seek immediate medical attention. Symptoms may include nausea, vomiting, abdominal pain, dizziness, and liver function abnormalities. There is no specific antidote for naltrexone overdose. Treatment should be symptomatic and supportive, with particular attention to hepatic status. Hemodialysis is not effective for removal due to extensive protein binding. Maintain hydration and monitor vital signs in clinical setting.
Storage
Store at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Keep in original blister packaging until administration to protect from moisture and light. Do not transfer to other containers. Keep out of reach of children and pets. Do not use if packaging appears compromised or tablets show signs of deterioration. Properly dispose of unused medication through take-back programs.
Disclaimer
SobrietyGuard is a prescription medication that requires medical supervision and should only be used under direction of a qualified healthcare provider. This information does not replace professional medical advice, diagnosis, or treatment. Individual results may vary. Not all patients will respond to treatment, and some may experience side effects. Always consult your healthcare provider before making changes to your treatment regimen.
Reviews
“After struggling with alcohol dependence for 15 years, SobrietyGuard provided the pharmacological support I needed to maintain abstinence. Combined with counseling, it reduced cravings significantly within the first month.” - Michael T., completed 9-month treatment
“As a addiction specialist, I’ve incorporated SobrietyGuard into comprehensive treatment plans with notable success. Patients report decreased craving intensity and improved ability to engage in therapeutic interventions.” - Dr. Eleanor Roberts, MD
“The gradual reduction in alcohol cravings allowed me to focus on rebuilding my life without constant preoccupation with drinking. The once-daily dosing made adherence straightforward.” - Sarah J., 6 months sober